Dyne Therapeutics, Inc. (DYN)
| Market Cap | 2.82B +100.8% |
| Revenue (ttm) | n/a |
| Net Income | -451.71M |
| EPS | -3.18 |
| Shares Out | 165.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,882,591 |
| Open | 18.09 |
| Previous Close | 18.41 |
| Day's Range | 16.63 - 18.60 |
| 52-Week Range | 8.06 - 25.00 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 38.25 (+124.47%) |
| Earnings Date | May 11, 2026 |
About DYN
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price target is $38.25, which is an increase of 124.47% from the latest price.
News
Dyne Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company highlighted progress on its FORCE platform, with BLA filed for DMD Exon 51 and DM1 trial enrollment completed. Commercial launch is targeted for next year, with confirmatory studies underway and a robust pipeline in FSHD, Pompe, and additional DMD exons. Cash runway extends into 2028.
Dyne Therapeutics completes enrollment in ACHIEVE trial of zeleciment basivarsen
Dyne Therapeutics (DYN) announced the completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial of zeleciment basivarsen in individuals with DM1.
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stag...
Dyne Therapeutics announces submission of BLA to U.S. FDA for z-rostudirsen
Dyne Therapeutics (DYN) announced the submission of a Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, for zeleciment rostudirsen, z-rostudirsen, 20 mg/kg Q4W for the...
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust and...
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...
Dyne Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
The discussion highlighted execution on DMD and DM1 programs, with commercial launches targeted for 2026 and a robust pipeline expansion leveraging the FORCE platform. Confirmatory trials are underway, regulatory engagement remains strong, and capital is being efficiently allocated to advance FSHD and other assets.
Dyne Therapeutics initiates FORZETTO trial of zeleciment rostudirsen
Dyne Therapeutics (DYN) announced the initiation of the Phase 3 FORZETTO trial of zeleciment rostudirsen in individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. The design of the...
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle ...
Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI
Evercore ISI lowered the firm’s price target on Dyne Therapeutics (DYN) to $33 from $34 and keeps an Outperform rating on the shares.
Dyne Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics Slides: AGM presentation
Dyne Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Dyne Therapeutics price target raised to $24 from $23 at Bernstein
Bernstein raised the firm’s price target on Dyne Therapeutics (DYN) to $24 from $23 and keeps a Market Perform rating on the shares. Biotech has had a strong start to…
Dyne Therapeutics reports Q1 EPS (73c), consensus (78c)
“Following positive topline data late last year, we continue to ramp up activities to support a potential launch of z-rostudirsen in DMD in the first quarter of 2027,” said John…
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 -
Dyne Therapeutics Quarterly report: Q1 2026
Dyne Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Dyne Therapeutics Earnings release: Q1 2026
Dyne Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier -
Dyne Therapeutics Proxy statement: Proxy filing
Dyne Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Dyne Therapeutics Proxy statement: Proxy filing
Dyne Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Dyne Therapeutics Proxy statement: Proxy filing
Dyne Therapeutics filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care exp...
Dyne Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
The company anticipates a pivotal year in 2026, with commercial launch preparations for DMD and a robust pipeline of eight clinical programs. Positive DMD data, regulatory alignment, and a differentiated platform support confidence in upcoming approvals and market entry.
Dyne Therapeutics announces data from Phase 1/2 Deliver trial of z-rostudirsen
Dyne Therapeutics (DYN) announced additional positive data from the ongoing Phase 1/2 Deliver clinical trial of zeleciment rostudirsen, z-rostudirsen, in individuals with Duchenne muscular dystrophy a...
Dyne Therapeutics initiates Phase 3 Harmonia trial of Z-Basivarsen in DM1
Dyne Therapeutics (DYN) announced the initiation of the Phase 3 Harmonia trial of zeleciment basivarsen, z-basivarsen, also known as DYNE-101, in individuals with myotonic dystrophy type 1, DM1. The d...